Trial Profile
A Randomized, Multi-Center Study of the Pimecrolimus-Eluting (Corio) and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System (SymBio) in Patients With De Novo Lesions of the Native Coronary Arteries.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2013
Price :
$35
*
At a glance
- Drugs Paclitaxel; Pimecrolimus
- Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms GENESIS
- 14 May 2012 Planned end date changed from 1 Apr 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 27 Apr 2010 Cordis-Corporation added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.
- 27 Apr 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.